Operating income before deduction of amortization: Vanda Pharma (VNDA)

The implementation of automated CNS molecule screening optimizes research, as confirmed by the monthly EBITDA trend, where the figure is recorded at 0.00. Growth is based on the patent protection of Hetlioz and strong pricing power within niche markets. The integration of precision neurotherapy into schizophrenia treatment standards creates an indispensable foundation for the business development of Vanda Pharmaceuticals (VNDA).

Vanda Pharmaceuticals (VNDA) Operating profit EBITDA: for the period 11/23/2025 - 11/11/2026

Summary analytical data breakdowns for Vanda Pharmaceuticals Inc. (VNDA)

- share price and consensus valuation forecast:

Quote Chart Vanda|VNDA - Price Target Chart

- company stock exchange capitalization indicators:

Market Capitalization Vanda Pharmaceuticals|VNDA - Real Price to Acquire Entire Company

- balance sheet equity data:

Net Asset Value per Share Vanda Pharmaceuticals|VNDA - Book Capitalization|Market Cap to Net Assets Ratio vandapharma.com|VNDA - Company Total Assets

- company total debt and liquidity indicators:

All Debt to Shareholders' Equity Ratio Vanda Pharmaceuticals|VNDA - Long-Term Debt to Equity|Current Liabilities to Capital Vanda Pharma|VNDA - Company Total Debt|Debt to Book Capitalization Ratio Vanda Pharmaceuticals|VNDA - Company Long-Term Debts|Company Short-Term Debts Vanda Pharmaceuticals|Immediate Liquidity Ratio vandapharma.com

- earnings and market multiples details:

VNDA - Net Profit|Net Profit Forecast Vanda Pharmaceuticals|VNDA - P/E Multiple|Forward P/E Multiple vandapharma.com|VNDA - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Vanda Pharmaceuticals|VNDA - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Vanda Pharmaceuticals|VNDA - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months vandapharma.com|VNDA - Earnings growth in current year|Earnings growth forecast for next year Vanda Pharmaceuticals

Fundamental company valuation:Vanda (VNDA)

This indicator measures the business's daily ability to generate cash flow from core operations, excluding non-cash asset depreciation expenses. For Vanda Pharmaceuticals (VNDA), whose developments are protected by a sovereign demand cycle, this underlying operational result before depreciation confirms the company's resilience as a defensive asset, reflecting the real efficiency of drug commercialization without the influence of macroeconomic fluctuations.

Who Vanda Pharmaceuticals competes with

ALKS (Alkermes Corp) - Profit before deduction of interest, taxes, depreciation and amortization|AVDL - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization atai.life ATAI|GHRS (GH Research) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization Mind Medicine (MindMed) Inc. (MNMD)|CMPS (Compass Pathways) - Operating profit EBITDA|Operating profit before deduction of amortization LB Corp (LBRX)|Operating profit EBITDA DRUG|CYBN (cybin.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Alto Neuroscience ANRO|NRx Pharmaceuticals Inc. (NRXP) - Profit before interest, taxes and amortization|CING: Operating profit before deduction of amortization|SILO: Profit before payment of interest, taxes and amortization|CPHI: Operating profit EBITDA|clearmindmedicine.com (CMND) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Psyence Biomedical|Operating profit before amortization SPRC (SciSparc Ltd.)|Operating profit EBITDA SEEL|virpaxpharma.com - Operating profit before amortization|Operating profit EBITDA KRTX (Karuna Therapeutics)